614 McKinley Place N.E.
173 articles with Bio-Techne
Bio-Techne To Host Conference Call On October 29, 2019, To Announce First Quarter 2020 Financial Results
Bio-Techne Corporation announced that management will host a conference call on Tuesday, October 29, 2019, at 8:00 a.m. CDT to review first quarter 2020 financial results.
This certification demonstrates Bio-Techne's commitment for providing high-quality serum and media that aligns with the quality excellence standards preferred by biotech, biopharmaceutical and pharmaceutical companies as well as academic researchers.
This new kit enables users to collect, manage and report Maurice results with the industry leading Empower® 3 Software from Waters™ Corporation.
Bio-Techne Corporation and Cygnus Technologies, part of Maravai LifeSciences, announced today a strategic partnership for the quantification of Chinese hamster ovary host cell proteins (CHO-HCP) on the ProteinSimple™-branded Ella™ immunoassay platform.
Bio-Techne Corporation reported its financial results for the fourth quarter ended June 30, 2019.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2019.
Under the terms of the agreement, Uman Diagnostics will supply Nf-L antibodies to Bio-Techne for use in its proprietary Simple Plex™ immunoassays on Ella.
Bio-Techne To Host Conference Call On August 6, 2019, To Announce Fourth Quarter 2019 Financial Results
CDT to review fourth quarter 2019 financial results.
This new cartridge format analyzes 32 samples for eight distinct analytes, bringing higher multiplex capabilities to the Ella platform.
Bio-Techne Announces Commercial Release Of RNAscope® HiPlex Assay: A Multiplex In Situ Hybridization Assay For Tissues
Expanding research tools for Spatial Genomics by combining molecular information with spatial context in one simple assay.
This award recognized the commitment of Bio-Techne's team in China to providing comprehensive support and reliable products and services for the Chinese Biotechnology industry.
Bio-Techne Receives Approval To Offer The ExoDx™ Prostate Intelliscore™ (EPI) Test In New York State
Bio-Techne today announced that it has received a clinical laboratory permit from the New York State Department of Health to provide its ExoDx Prostate IntelliScore (EPI) test in New York, providing a valuable tool to help Urologists rule out unnecessary prostate biopsies.
Bio-Techne Corporation announced it has reached agreement to acquire all of the stock of B-MoGen Biotechnologies Inc.
Bio-Techne's New Exosome-Based Liquid Biopsies Helping To Advance Personalized Care In Lung Cancer Diagnostics
Bio-Techne announced the publication of a recent validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne's Exosome Diagnostics brand may be used to assess the mutational status of the Epidermal Growth Factor Receptor gene in patients with non-small cell lung cancer.
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference on Wednesday, June 5th, 2019, at 9:30 a.m. EDT.
The conference will be held at the Grand Hyatt Hotel in New York City.
Roche expands partnership with Bio-Techne to offer drug discovery researchers new chromogenic detection options for mRNA ISH tissue analysis
New Roche detection kits, combined with Bio-Techne's ACD RNAscope® reagent kits, increase singleplex and multiplex testing capabilities on automated platform
Bio-Techne Corporation announced that Jim Hippel, Chief Financial Officer will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15th, 2019, at 2:20 p.m. PDT.
Bio-Techne Corporation reported its financial results for the third quarter ended March 31, 2019.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended March 31, 2019.